Probably most have seen the Bell Potter report yesterday. But in case some have missed it, they still are hopeful, despite a heavy downgrade. An excerpt:
"Our new target price is $1.10 (was $3.30). We see the potential for a re-rating coming out of the company’s advice from the FDA in August 2012."
It's going to be a very tense 2 months wait but good luck to holders.
Probably most have seen the Bell Potter report yesterday. But in...
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
